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a  b  s  t  r  a  c  t
The  complement  system,  as part  of  innate  immunity,  is  activated  immediately  after  trauma  in  response  to
various pathogen-  and  danger-associated  molecular  patterns  (PAMPs  and  DAMPs),  and  helps  to  eliminate
microorganisms  and  damaged  cells.  However,  recent  data  indicate  an  extended  role  of  complement  far
beyond  pure  “killing”,  which  includes  regulation  of the  cytokine/chemokine  network,  inﬂuencing  physi-
ological  barriers,  interaction  with  the  coagulation  cascade,  and  even  involvement  with  bone metabolism
and  repair.  Complement-induced  hyper-activation  and  dysfunction  reveal  the  dark  side  of  this  system,
leading  to  complications  such  as  sepsis,  multiple-organ  dysfunction,  delayed  fracture  healing,  and  unfa-
vorable  outcome.  Thus,  the  present  review  focuses  on  less  known  regulatory  roles  of the  complement
system  after  trauma  and  during  fracture  healing,  rather  than  on  its  bacterial  and cellular  “killing func-
tions”.  In particular,  various  complement  crosstalks  after trauma,  including  the  coagulation  cascade  and
apoptosis  system,  appear  to be  crucially  involved  early  after  trauma.  Long-term  effects  of  complement
on  tissue  regeneration  after  fracture  and  bone  turnover  are  also  considered,  providing  new  insights  into
innate  immunity  in local  and systemic  complement-driven  effects  after trauma.. Introduction
Traumata are accountable for an increasing portion of the
lobal burden of disease [1,2], and reﬂect a major humane, socio-
conomic, clinical, and scientiﬁc challenge. Trafﬁc accidents with
ultiple injuries and fractures are the number one killer of young
eople and the leading cause of death during the ﬁrst half of life
up to age 45) [3]. Survival of patients after severe tissue trauma,
or example, after multiple fractures, requires an adequate surgi-
al management and even more importantly, as a conditio sine qua
on, an effective molecular and cellular danger response to repair
amaged tissue. Various ﬂuid-phase and cellular defense systems
ave evolved to clear any pathogen- (PAMPs) or danger-associated
olecular patterns (DAMPs) generated by microorganisms or the
ost tissue, respectively [4,5]. Early after trauma, the comple-
ent system, coagulation cascade, and neutrophils together with
he cytokine/chemokine network act in conjunction as the “ﬁrst
ine of defense” of innate immunity, initiating a systemic danger
esponse to overcome the insult [6]. The complement system is
onsidered to be a main trigger and driver of whole body inﬂam-
ation, clinically manifested as systemic inﬂammatory response
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syndrome (SIRS). During trauma-induced SIRS, there is an almost
synchronic generation and release of pro- and anti-inﬂammatory
cytokines/chemokines [7,8]. In the additional presence of PAMPs or
bacteria, deﬁned as sepsis, complement activation results in C3b-
dependent opsonization of microorganisms, C3a- and C5a-induced
recruitment of leukocytes, and formation of the membrane attack
complex (C5b-9) to clear bacteria and PAMPs. Even if the comple-
ment system with its potent activation products was  designed to
prevent host organism destruction by killing invading microorgan-
isms and damaged cells, it might nevertheless also kill the host itself
through an uncontrolled and extensive inﬂammatory and coagu-
latory response with resulting multiple organ dysfunction [9,10]
(Fig. 1).
However, there is evidence, that the complement system in par-
ticular acts far beyond its apparent and obscure killing mechanisms
by inﬂuencing tissue repair, especially after severe trauma and con-
comitant bone fractures [11].
2. Trauma-induced complement activation – too much
killing?
How does the traumatized, dying cell warn the innate immune
system of danger [12]? A most effective molecular “early alarm
Open access under CC BY-NC-ND license.system” for both DAMPs and PAMPs consists of the coagulation [13]
and complement cascades [14,15]. In particular, trauma-induced
exposure of negatively charged surfaces, released tissue factors,
the generation of antigen–antibody complexes, released bacterial





































lig. 1. Trauma-induced early activation of the complement and coagulation syste
olecules. PAMPS, pathogen-associated molecular patterns; DAMPS, danger associa
rgan  dysfunction syndrome; MOF, multiple organ failure.
ipopolysaccharides, and pathogenic carbohydrate structures
mong others can be sensed by the complement and coagulation
ascades, which are excessively activated early after trauma.
ecently, we have shown in a prospective multicenter study in 40
olytrauma patients (mean injury severity score [ISS] = 30.3 ± 2.9)
n early, massive activation of complement (as evidenced by
lmost abolished CH50 values), discriminative between lethal and
on-lethal outcome. Serum levels of the complement activation
roducts C3a and C5a were signiﬁcantly elevated throughout the
0-day observation period and correlated with the severity of trau-
atic brain injury and survival. The soluble terminal complement
omplex sC5b-9 and mannose-binding lectin (MBL) displayed a
iphasic response after trauma, with an early increase and subse-
uent collapse over at least 24 h [16]. Other groups have also found
n trauma patients who developed acute respiratory failure (ARDS)
r multiple-organ dysfunction (MODS), a posttraumatic systemic
epletion of C3 and C5 with enhanced C3a/C3 ratios [17–19]. In a
ono-centered study including 208 major trauma patients, early
eneration of sC5b-9 was found to correlate with the ISS and devel-
pment of MODS [20]. Furthermore, the alternative pathway was
uggested as the predominant complement activation pathway
fter trauma [20]. The resulting SIRS appears to be associated with
nhanced concentrations of complement activation products, as
een in various conditions [21]. In an experimental setting of rodent
lunt thorax trauma, dramatic changes in blood neutrophil func-
ion were found, including an impairment of the phagocytic uptake
nd chemotactic activity, and an increase in the oxidative burst
esponse, which may  increase the bacterial impact and enhance
ellular stress on the intact cells. Interestingly, these cellular defects
ere all prevented by blockade of C5a [22,23]. Systemic C5a is also
nown to effectively induce remote organ injury or delayed healing
e.g. delayed fracture healing). Because C5a is a potent inductor of
ll classical signs of inﬂammation (pain, heat, redness, swelling, and
oss of function), this anaphylatoxin represents an ideal target for crosstalking systems, resulting in “killing” of pathogens and clearance of danger
olecular patterns; SIRS, systemic inﬂammatory response syndrome; MODS, multiple
immune modulation to prevent development of direct and remote
organ injury, such as ARDS and MODS [10,22], and even the devel-
opment of non-unions [24,25]. Overall, in systemic inﬂammatory
conditions, C5a may  not only be considered as “too much of a good
thing” [26], but as a consequence can result in “too much killing”.
3. Complement crossroads after trauma
Trauma-induced rapid activation of the serial and interactive
proteases of the complement and coagulation systems [27] leads
not only to an early clotting response (to control blood loss),
but also to a simultaneous early inﬂammatory response to con-
trol cell trauma (DAMPs) and to eliminate potentially invasive
microorganisms (PAMPs). The coagulation factor Xa and thrombin
as well as C3 and C5 have been particularly shown to be molecu-
lar triggers for both systems [14]. The activated coagulation- and
complement-products (ﬁbrin, C3a, and C5a) can chemotactically
recruit polymorphonuclear neutrophils (PMNs) and macrophages
to the cell-trauma site. There, the phagocytes recognize the danger
signals via the DAMP receptors and convert them into a cellular
response. This was postulated for example for the C5a receptor
(C5aR), which can alone, or possibly in crosstalk with Toll-like
receptors (TLRs) [28] or after dimerization with other receptors
(e.g. CCR5) [29], translate the danger signals into a cellular response
to induce an inﬂammatory reaction. In the clinical setting, trauma
patients with low C3a levels demonstrated a correlation between
sC5b-9 levels and plasma concentrations of prothrombin fragments
1 and 2 (produced upon thrombin generation), supporting the
idea of a trauma-relevant, intensive crosstalk between the com-
plement and coagulation cascades [14,27,30]. Furthermore, factor
VII-activating protease (FSAP), which is activated by histones and
nucleosomes from damaged cells, has recently been shown to be
activated in multiple trauma patients and to generate C5a. Imme-
diately after injury, a large increase in nucleosomes and circulating



























aig. 2. Complement functions beyond “killing”: systemic and local complement act
Ø,  macrophage; PMN, polymorphonuclear neutrophil; Mono, monocyte; MSC, me
PS,  lipopolysaccharide; RANKL, receptor activator of NF-kB ligand.
SAP activity was detected and a correlation between FSAP activity
nd C5a concentrations was found [31]. On a cellular level, there
s also a procoagulant shift after exposure to C5a, as in response
eutrophils generate tissue factor (TF) and mast cells enhance
he production of plasminogen activator inhibitor (PAI-1) [30,32],
hich may  not only play an important role in ARDS [33], but also
nﬂuence hematoma formation after bone fractures.
The complement system also inﬂuences physiological barri-
rs. For example, zonulin, which is related to the serine proteases
ASP-1 and C1qrs, regulates tight junctions in epithelial and
ndothelial cells [34]. Recently, zonulin was found to generate C5a
ndependently of the canonical pathways and thereby may  con-
ribute to development of organ dysfunction, as seen for acute lung
njury [34].
Another important crosstalk in the pathophysiology after
rauma and fracture involves the apoptosis cascades (for “pro-
rammed suicidal killing”) and the complement system. The
ro-apoptotic serine protease granzyme B was found in enhanced
oncentrations in neutrophils and lymphocytes early after multiple
njury [35]. Furthermore, a new interaction interface for granzyme
 and C3a-/C5a-generation has been presented [35] Similarly, the
lasma level of pro-apoptotic aspartic protease cathepsin D was
igniﬁcantly increased in multiple injured patients and, more-
ver, was capable of cleaving C5, generating biologically active
5a [36]. C5a in turn can delay neutrophil apoptosis, as found
fter trauma and during sepsis [37], which may  enhance hostn effecting fracture healing. MAC: IL, interleukin; MAC, membrane attack complex;
ymal stem cell; CRegs, complement regulatory protein; TLR4, Toll-like receptor 4;
damage [6]. In terms of a fracture, this may  theoretically mean pro-
longed hematoma clearance, sustained inﬂammation, and delayed
recruitment of osteoblast and osteoclast progenitors required for
regeneration.
Interestingly, viable neutrophils primed by granulocyte/
macrophage colony-stimulating factor and stimulated with either
C5a or TLR4 agonist also exhibited enhanced survival and released
neutrophil extracellular traps (NETs), which bind and kill microor-
ganisms [38]. The complement system and TLRs as two central
columns of innate immunity are activated by most PAMPs and con-
tribute to an intensive crosstalk between the innate and adaptive
immune response [39–41], leading to the elimination of infection
and induction of tissue repair.
4. Failure of danger management after trauma:
complementopathy and complications
Molecular danger management is physiologically tightly con-
trolled by many regulatory systems. After severe trauma and
fractures, hyper-activation, imbalance and, ﬁnally, failure of dif-
ferent regulatory systems have been reported [6]. In the case of the
serine protease system, this gives rise to an early trauma-induced
coagulopathy [6,13] and a nearly simultaneous complementopa-
thy [42]. Early coagulopathy is of critical prognostic importance
for polytrauma patients, because regardless of the severity of the
injury, the post-trauma mortality rate is elevated fourfold [43].
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ith regard to the complement system, in addition to early activa-
ion [16,19], an early dysregulation of the complement regulatory
roteins (CRegs) in polytrauma patients was also described by
ur research group [42]. Thereby, a reduction in the comple-
ent inhibitors CD46 and CD59 found on neutrophil granulocytes
trongly correlated with increasing trauma severity in the presence
f hemorrhagic shock [42]. Furthermore, key ﬂuid-phase inhibitors
f complement, including factor I and C4b-binding protein (C4BP),
ere signiﬁcantly reduced early after trauma [20]. Because both
he coagulation and complement systems are important in the
arly acquisition and processing of PAMPs and DAMPs, the early
ost-traumatic occurrence of coagulopathy and complementopa-
hy are clearly critical for the development of post-traumatic
omplications, organ and immune dysfunction, and delayed tissue
egeneration. Development of MODS is regularly associated with
lood barrier dysfunction and failure. Remarkably, the anaphyla-
oxin C5a and sC5-9 have also been proposed to play a decisive role
n the development of blood barrier dysfunction, particularly after
raumatic brain injury [23,44]. For a bench-bedside transfer, ﬁrst
omplement inhibitor strategies are under investigation, includ-
ng C1q inhibition early after trauma, targeting changes in the IL-6
erum levels (as primary endpoint) and occurrence of inﬂammatory
omplications (as secondary endpoint), such as ARDS or MODS [45].
. Role of complement in fracture healing: terra incognita
Although the data regarding the role of complement in SIRS
evelopment and concomitant complications are incomplete, even
ess is known about its inﬂuence on bone. Recent ﬁndings indi-
ated a constant crosstalk between the bone and immune system,
hich resulted in the emerging ﬁeld of osteoimmunology [11]. As
one acts as a reservoir for bone marrow, and, therefore, numerous
mmune progenitors and mature cells, the “immune function” of
one cells themselves has not been extensively studied. Our group
as shown that both osteoblasts and osteoclasts are important
layers in the regulation of the immune response after trauma and
re able to act as inﬂammatory cells post trauma (Fig. 2). The bone
ells are able to respond to inﬂammatory signals, including PAMPs
nd complement anaphylatoxins, amplify them, and recruit other
ells necessary for tissue repair. However, to what extent bone cells
egulate their local and systemic inﬂammatory environment is not
lear. Moreover, as complement factors and complement recep-
ors are locally expressed during the whole healing phase, and not
nly during the initial acute inﬂammatory phase, it is clear that
omplement is in this context a “regulator” rather than a “killer”.
. New insights into the crosstalk of complement and bone
Clinical data indicate that several disorders, which are associ-
ted with complementopathies, may  also affect bone. Examples are
ystemic lupus erythematosus (SLE) and rheumatoid arthritis. SLE,
aused by a deﬁciency in complement component C1q, is known
o be associated with bone loss and an increased risk of fractures
46,47]. Rheumatoid arthritis, which is characterized by a severe
egeneration of both bone and cartilage tissues of the joints and by
ystemic osteopenia, is accompanied by C3c and C9 deposition in
ffected joints and decreased CD59 expression [48]. Recently, these
bservations were conﬁrmed by Neumann et al., who described
he expression of factor B, C3, C5b-C9, and complement receptors
3aR and C5aR in rheumatoid synovia [49]. Wang and colleagues
bserved a strongly increased expression of complement factors
, C5, C7, and C9 in synovial membranes of osteoarthritic patients,
hich correlated with increased membrane attack complex (MAC)
ormation [50]. Moreover, they observed that CD59-deﬁciency
ccentuated the osteoarthritic phenotype in a mouse model,munology 25 (2013) 73– 78
subjected to destabilization of the medial meniscus. Additionally,
mice deﬁcient in different components of MAC, including C5 or
C6, were protected against osteoarthritis. The authors suggested
that the dysregulation of complement might play a key role in the
pathogenesis of osteoarthritis. There is also evidence that C5aR
may  play a crucial role in periodontitis, because mice lacking the
receptor were protected from periodontal bone loss [51,52].
Conﬁrming the clinical data of delayed fracture healing after
a major trauma impact, our group demonstrated in a rat model
of severe trauma that fracture healing was considerably impaired
after an additional blunt chest trauma, a strong inducer of posttrau-
matic systemic inﬂammation. We  found that the acute systemic
inﬂammation altered the cellular composition and the cytokine
expression in the fracture hematoma and considerably decreased
bone formation as well as the mechanical competence of the frac-
ture callus in the late phase of healing [53,54]. Both C5aR [55]
and C3aR (unpublished data) were strongly expressed not only
by immune cells during the early inﬂammatory phase of fracture
healing, but also by osteoblasts, hypertrophic chondroblasts, and
osteoclasts during the entire healing period in a spatial and tempo-
ral pattern both in zones of intramembranous and endochondral
ossiﬁcation. Moreover, the disturbed bone healing in the com-
bined trauma model was  attenuated after the application of the
C5a-receptor antagonist PMX-53, indicating a mechanistic role for
complement activation [25].
Taken together, the clinical and experimental data clearly sug-
gest a crucial function of complement in disorders affecting bone
and in bone regeneration; however, the underlying molecular
mechanisms remain unclear. Usually, complement proteins are
considered to be expressed mainly by immune cells, such as mono-
cytes and macrophages, as well as by hepatocytes and epithelial
cells. The ﬁrst evidence of the regulatory role of complement in
bone was  described more than two  decades ago by Sakiyama et al.,
who reported C1s expression in the primary ossiﬁcation center dur-
ing bone development. C1s was expressed mainly by hypertrophic
chondrocytes, suggesting that C1s, which can cleave collagen due
to its serine protease activity, might play a role in cartilage degrada-
tion during ossiﬁcation [56,57]. Andrades and colleagues observed
the expression of factor B and C3 by chondroblasts in the growth
plate, the site of endochondral bone formation during longitudi-
nal growth of bones, whereas C5 and C9 were localized mainly
in the hypertrophic zone, where chondrocytes are replaced by
osteoblasts. Thus, they suggested that the alternative pathway of
complement activation may  play a role in the turnover of carti-
lage to bone during bone development [58]. However, the exact
molecular mechanism of this regulation needs to be studied more
precisely.
7. Bone cells: victims or offenders after fracture?
Our recent in vitro studies revealed the expression of the
complement zymogens C3 and C5, the receptors C3aR and C5aR,
and multiple regulators, such as CD46 (MCP, membrane co-factor
of proteolysis), CD55 (DAF, decoy accelerating factor), and CD59
(MAC inhibitor) on undifferentiated and differentiated human mes-
enchymal stem cells (MSC) and osteoblasts [59] (Fig. 2). The strong
up-regulation of both anaphylatoxin receptors during osteogenic
differentiation indicates that osteoblasts might be effector cells for
activated complement [11]. Indeed, we observed ligand-induced
internalization of C3aR and C5aR in human osteoblasts [59],
whereas Schraufstatter and colleagues demonstrated the same
mechanism in undifferentiated MSC  [60]. Receptor internalization
is known to activate intracellular signaling pathways via Ras,
MEK, and ERK1/2 [21,60,61]. As in immune cells, anaphylatoxins
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Fig. 2). Pobanz et al. found that C5a considerably increased IL-1-
nduced release of IL-6 from osteoblast-like MG-63 cells [62]. Our
roup conﬁrmed these data, demonstrating a synergistic effect of
5a and IL-1 on the expression and release of IL-6 and IL-8 by
uman osteoblasts [59]. The interaction of IL-1 and C5a observed
n these studies may  result from crosstalk down-stream in the
ignaling pathways. These observations indicate that activated
omplement may  induce an inﬂammatory response of osteoblasts,
articularly in a pro-inﬂammatory environment, such as the early
racture hematoma. Furthermore, osteoblasts can produce the
omplement zymogens C3 and C5 following stimulation with
,25-dihydroxyvitamin D3 [59,63,64], further indicating the
rucial role of complement in bone metabolism.
Another important function of complement anaphylatoxins is
he recruitment of immune cells to the inﬂammation site. Studies
y Schraufstatter et al. and our group revealed that C3a and C5a
re also powerful chemokines for MSC  [60] and osteoblasts [55].
he migration of MSC  and osteoblasts toward a C3a or C5a gradient
ould be blocked by the application of the corresponding receptor
ntagonist, conﬁrming the speciﬁcity of the effect. We observed
 signiﬁcantly stronger migration of osteoblasts in comparison to
ndifferentiated MSC, which could be explained by an increase
n C5aR expression during osteogenic differentiation [55]. Osteo-
lasts, the bone resorbing cells, can efﬁciently cleave C5 to its active
orm, C5a, thereby possibly attracting osteoblasts during fracture
ealing and bone remodeling [59]. These data indicate that comple-
ent anaphylatoxins may  modulate the recruitment of osteoblasts
uring bone remodeling and regeneration, thus supporting bone
ormation.
However, the literature indicates that complement anaphyla-
oxins may  also modulate bone erosion. Osteoclast formation has
een shown to be directly and indirectly inﬂuenced by comple-
ent. Osteoblast and osteoclast activity are strictly coupled via the
ANKL/RANK/OPG system [65]. Osteoclast formation and activity
s induced by RANKL (receptor activator of NF-kB ligand), which
s released by osteoblasts and binds to its receptor RANK on the
urface of osteoclast precursor cells. OPG (osteoprotegerin) is also
eleased by osteoblasts and acts as a decoy receptor, inhibiting
ANKL activity [65]. C3a and C5a have been shown to stimu-
ate RANKL expression in osteoblasts, thus indirectly increasing
steoclast formation [59,64,66]. By blocking C3aR and C5aR in
ixed human bone marrow cultures, Tu et al. showed that the
naphylatoxin receptors are necessary for osteoclastogenesis [66].
here is evidence that complement anaphylatoxins may  also pro-
oke a direct inﬂuence on osteoclast formation. We  demonstrated
hat osteoclast-like cells can be generated in vitro by stimula-
ion of monocytes with C3a and C5a in the absence of RANKL
59].
In conclusion, clinical and experimental data suggest a role for
omplement in bone metabolism, inﬂammatory bone disorders,
nd bone healing. Central complement components, including C3
nd C5, are produced by bone cells. Osteoclasts can efﬁciently
leave C5 to its active form, C5a. Complement anaphylatoxins
nduce the migration and inﬂammatory response of osteoblasts and
irectly and indirectly regulate osteoclast formation. Further stud-
es are needed to elucidate the role of complement in inﬂammatory
nd infectious bone disorders and to clarify whether complement
ould be a promising therapeutic target.
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